Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 22, Issue 9, 2006, Pages 825-829

  Núñez, María José ^a   Martín Carbonero, Luz ^a   Moreno, Victoria ^a   Valencia, Eulalia ^a   Garcia Samaniego, Javier ^a   Del Castillo, Juan González ^a   Barreiro, Pablo ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTHRALGIA; ARTICLE; BONE ATROPHY; BONE MARROW TOXICITY; BONE PAIN; CHRONIC HEPATITIS; CHRONIC KIDNEY FAILURE; DRUG FATALITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SPAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HOSPITALIZATION; HUMANS; MALE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SPAIN;

EID: 33751033876     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.825     Document Type: Article

References (25)

1. Palella F, Delaney M, Moorman C, et al.: Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998;338:853-860.
2. Mocroft A, Brettle R, Kirk O, et al.: Changes in the cause of death among HIV-positive subjects across Europe: Results from the EuroSIDA study. AIDS 2002;16:1663-1671.
3. Valdez H, Chowdhry T, Asaad R, et al.: Changing spectrum of mortality due to HIV: Analysis of 260 deaths during 1995-99. Clin Infect Dis 2001;32:1487-1493.
4. Sepkowitz K: Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-230.
5. Kaplan J, Hanson D, Dworkin M, et al.: Epidemiology of HIV-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30 (Suppl):5-14.
6. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-497.
7. Martin-Carbonero L, Soriano V, Valencia E, et al.: Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1467-1471.
8. Fellay J, Boubaker K, Ledergerber B, et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet 2001;358:1322-1327.
9. Carr A and Cooper D: Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
10. Chen R, Westfall A, Mugavero M, et al.: Duration for highly active antiretroviral therapy regimens. Clin Infect Dis 2003;37:714-722.
11. Mocroft A, Youle M, Moore A, et al.: Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment center. AIDS 2001;26:185-194.
12. Wanke C, Falutz J, Shevitz A, et al.: Clinical evaluation and management of metabolic and morphologic abnormalities associated with HIV. Clin Infect Dis 2002;34:248-259.
13. Powderly W: Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002;29(Suppl.):28-40.
14. Schambelan M, Benson C, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an IAS-USA panel. J Acquir Immune Defic Syndr 2002;31:257-275.
15. Sulkowski M, Thomas D, Chaisson R, et al.: Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
16. Den Brinker, Wit F, Wertheim-van Killen P. et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
17. Nuñez M, Lana R, Mendoza J et al.: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-431.
18. Mocroft A, Phillips A, Soriano V, et al.: Reasons for stopping antiretrovirals used in an initial HAART regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005;21:743-752.
19. Soriano V, Puoti M, Sulkowski M, et al.: Care of patients with hepatitis C and HIV-coinfection. Updated recommendations from the HCV-HIV International Panel. AIDS 2004;18:1-12.
20. Blanco F, Garcia-Benayas T, Cruz J, et al.: First-line therapy and mitochondrial damage: Different nucleosides, different findings. HIV Clin Trials 2003;4:11-19.
21. Moyle G, Datta D, Mandalia S. et al.: Hyperlactataemia and lactic acidosis during antiretrovirul therapy: relevance, reproducibility and possible risk factors. AIDS 2002;16:1341-1349.
22. Falcó V, Rodriguez D. Ribera E, et al.: Severe nucleoside-associated lactic acidosis in HIV-infected patients: Report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-846.
23. Mina J, Corey B, James I, et al.: Chronic hyperlactatemia in HIV-infected patients taking antirctroviral therapy. AIDS 2001;15:717-723.
24. Boubaker K, Flepp M, Sudre P, et al.: Hyperlactatemia and antiretroviral therapy: The Swiss HIV cohort study. Clin Infect Dis 2001;33:1931-1937.
25. Imhof A, Lederberger B, Günlhard H. et al.: Risk factors for and outcome of hyperlactatemia in HIV-infected persons: Is there a need for routine lactate monitoring? Clin Infect Dis 2005;41:721-728.